| Literature DB >> 35329854 |
Carolina Arriagada-Vargas1, María Teresa Abeleira-Pazos1, Mercedes Outumuro-Rial1, Eliane García-Mato1, Iván Varela-Aneiros1, Jacobo Limeres-Posse1, Pedro Diz-Dios1, Márcio Diniz-Freitas1.
Abstract
The available literature on the orthodontic treatment of patients with rare disorders is extremely scarce. The aim of this study was to analyze the diagnosis and orthodontic treatment of a group of 94 individuals with rare diseases, referred for orthodontic evaluation to a university special care dentistry center (University of Santiago de Compostela, Spain). We created a control group of 94 systemically healthy individuals, paired by sex and age range. For all participants, we recorded their dental and skeletal abnormalities, oromotor dysfunctions and the characteristics of their orthodontic treatment. Some of the morphological and functional abnormalities were more prevalent in the rare disorders group than in the control group, including dental agenesis, microdontia, enamel defects, maxillary hypoplasia, overbite, cleft lip/palate, mouth breathing, atypical swallowing, lingual/labial interposition, labial incompetence, modified consistency diet, bruxism, and muscle tone abnormalities. Compared with the control group, the 56 patients with rare disorders who underwent orthodontic treatment required more desensitization sessions, used mixed appliances (fixed and removable) more often and for longer periods and had more frequent complications, such as gingivitis, caries, mucosal ulcers and recurrent debonding of the device. In conclusion, for selected patients with rare disorders, it is feasible to perform orthodontic treatment, whose planning will be determined by the dental-skeletal abnormalities and oromotor dysfunctions. Although complications are more frequent, they can typically be solved without having to stop treatment.Entities:
Keywords: dental care; dysgnathia; malocclusion; orofacial manifestations; orthodontics; rare diseases
Year: 2022 PMID: 35329854 PMCID: PMC8954363 DOI: 10.3390/jcm11061527
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Distribution of the rare diseases study group.
| Disease Category, ( | Diagnosis, ( |
|---|---|
| Neurological disorders (25) | Basal encephalocele (1) |
| SYNGAP1-related developmental and epileptic encephalopathy (1) | |
| Pontocerebellar hypoplasia (2) | |
| Hypoplasia/agenesis of the corpus callosum (2) | |
| Periventricular leukomalacia (3) | |
| Dandy–Walker malformation (1) | |
| Arnold–Chiari malformation type 1 (1) | |
| Microcephaly (3) | |
| Dravet syndrome (1) | |
| Endosteal sclerosis-cerebellar hypoplasia syndrome (1) | |
| Chromosome 15 inversion–duplication syndrome (1) | |
| Joubert syndrome (1) | |
| 2q23.1 microdeletion syndrome (1) | |
| Rett syndrome (3) | |
| Shapiro syndrome (1) | |
| Tourette syndrome (1) | |
| West syndrome (1) | |
| Global developmental disorders (12) | Tay–Sachs disease (1) |
| Cri-du-Chat syndrome (1) | |
| De Grouchy syndrome (1) | |
| Kabuki syndrome (2) | |
| Xp22.3 microdeletion syndrome (1) | |
| Prader–Willi syndrome (2) | |
| Smith–Magenis syndrome (1) | |
| Williams syndrome (3) | |
| Skeletal dysplasia (10) | Achondroplasia (1) |
| Arthrogryposis (1) | |
| Chondrodysplasia (1) | |
| Rhizomelic skeletal dysplasia of unknown origin (1) | |
| Blount disease (1) | |
| Spina bifida (1) | |
| Radioulnar terminal transverse meromelia (1) | |
| Osteogenesis imperfecta (1) | |
| Myhre syndrome (1) | |
| Sotos syndrome (1) | |
| Head and neck syndromes (10) | Cherubism (2) |
| Apert syndrome (1) | |
| CHARGE syndrome (2) | |
| Hallermann–Streiff syndrome (1) | |
| Pierre Robin syndrome (3) | |
| Treacher Collins syndrome (1) | |
| Genodermatosis (9) | Ectodermal dysplasia (7) |
| Hypomelanosis of Ito (1) | |
| Gorlin–Goltz syndrome (1) | |
| Sensory disorders (4) | Leber’s congenital amaurosis (1) |
| Zellweger spectrum (1) | |
| Congenital rubella (1) | |
| Goldenhar syndrome (1) | |
| Intellectual/cognitive impairment (11) | Congenital hypothyroidism (1) |
| GRIN 1 mutation (1) | |
| Alpha thalassemia X-linked intellectual disability syndrome (1) | |
| Coffin–Siris syndrome (2) | |
| Chromosome 22q11.21 duplication syndrome (1) | |
| Smith–Lemli–Opitz syndrome (1) | |
| Fragile X syndrome (4) | |
| Miscellaneous (13) | Spinal muscular atrophy (1) |
| Congenital citrullinemia type 1 (1) | |
| Glycogenosis type 1b (1) | |
| Minicore myopathy (1) | |
| Idiopathic thrombocytopenic purpura (1) | |
| Alagille syndrome (1) | |
| Beckwith–Wiedemann syndrome (2) | |
| Sanfilippo syndrome (1) | |
| Short bowel syndrome (1) | |
| 1:9 (p31.2, q31) chromosomal translocation (1) | |
| Chromosome 2 translocation (1) | |
| Partial trisomy of the long arm of chromosome 16 (1) |
Oral/dental manifestations of the rare diseases patient group, distributed by categories based on target organ/system.
| Dental Abnormalities | ND | GDD | SkD | HNS | G | SnD | ICI | M | Total | |
|---|---|---|---|---|---|---|---|---|---|---|
|
| Chronology | 1 | 0 | 1 | 3 | 0 | 1 | 2 | 0 | 8 |
| (4.0) | (0) | (10.0) | (30.0) | (0) | (25.0) | (18.1) | (0) | (8.5) | ||
| Ectopia | 1 | 2 | 4 | 6 | 1 | 0 | 1 | 3 | 18 | |
| (4.0) | (16.7) | (40.0) | (60.0) | (11.1) | (0) | (9.0) | (23.1) | (19.1) | ||
|
| Agenesis | 2 | 2 | 4 | 3 | 9 | 2 | 0 | 1 | 23 |
| (8.0) | (16.7) | (40.0) | (30.0) | (100) | (50.0) | (0) | (7.7) | (24.5) | ||
| Supernumerary | 2 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 5 | |
| (8.0) | (0) | (0) | (0) | (11.1) | (25.0) | (9.0) | (0) | (5.3) | ||
|
| Size | 0 | 0 | 0 | 0 | 4 | 1 | 1 | 0 | 6 |
| (0) | (0) | (0) | (0) | (44.4) | (25.0) | (9.0) | (0) | (6.4) | ||
| Appearance | 0 | 0 | 1 | 1 | 4 | 2 | 0 | 0 | 8 | |
| (0) | (0) | (10.0) | (10.0) | (44.4) | (50.0) | (0) | (0) | (8.5) | ||
|
| Enamel | 0 | 2 | 0 | 3 | 1 | 1 | 2 | 2 | 11 |
| (0) | (16.7) | (0) | (30.0) | (11.1) | (25.0) | (18.1) | (15.4) | (11.7) | ||
| Dentin | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | |
| (0) | (0) | (10) | (0) | (0) | (0) | (0) | (0) | (1.1) | ||
ND, neurological disorders; GDD, global developmental disorders; SkD, skeletal dysplasia; HNS, head and neck syndromes; G, genodermatosis; SnD, sensory disorders; ICI, intellectual/cognitive impairment; M, miscellaneous.
Orthodontic oral manifestations of the rare diseases patient group, distributed by categories according to target organ/system.
| Orthodontic Variables | ND | GDD | SkD | HNS | G | SnD | ICI | M | Total | |
|---|---|---|---|---|---|---|---|---|---|---|
|
| I | 5 | 1 | 0 | 1 | 5 | 1 | 1 | 4 | 18 |
| (20.0) | (8.3) | (0) | (10.0) | (55.6) | (25.0) | (9.1) | (30.8) | (19.1) | ||
| II | 15 | 5 | 4 | 5 | 0 | 0 | 6 | 2 | 37 | |
| (60.0) | (41.7) | (40.0) | (50.0) | (0) | (0) | (54.5) | (15.4) | (39.4) | ||
| III | 5 | 6 | 6 | 4 | 4 | 3 | 4 | 7 | 39 | |
| (20.0) | (50.0) | (60.0) | (40.0) | (44.4) | (75.0) | (36.4) | (53.8) | (41.5) | ||
|
| Maxillary | 4 | 4 | 3 | 2 | 4 | 1 | 2 | 3 | 23 |
| (16.0) | (33.3) | (30.0) | (20.0) | (44.4) | (25.0) | (18.2) | (23.1) | (24.5) | ||
| Mandibular | 7 | 4 | 2 | 2 | 0 | 0 | 3 | 3 | 21 | |
| (28.0) | (33.3) | (20.0) | (20.0) | (0) | (0) | (27.3) | (23.1) | (22.3) | ||
| Mixed | 14 | 4 | 5 | 6 | 5 | 3 | 6 | 7 | 50 | |
| (56.0) | (33.3) | (50.0) | (60.0) | (55.6) | (75.0) | (54.5) | (53.8) | (53.2) | ||
|
| Mesofacial | 10 | 7 | 7 | 7 | 9 | 2 | 9 | 5 | 56 |
| (40.0) | (58.3) | (70.0) | (70.0) | (100) | (50.0) | (81.8) | (38.5) | (59.6) | ||
| Brachyfacial | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | |
| (12.0) | (8.3) | (0) | (0) | (0) | (0) | (0) | (0) | (4.3) | ||
| Dolichofacial | 12 | 4 | 3 | 3 | 0 | 2 | 2 | 8 | 34 | |
| (48.0) | (33.3) | (30.0) | (30.0) | (0) | (50.0) | (18.2) | (61.5) | (36.2) | ||
|
| Open bite | 7 | 3 | 3 | 2 | 0 | 2 | 3 | 6 | 26 |
| (28.0) | (25.0) | (30.0) | (20.0) | (0) | (50.0) | (27.3) | (46.2) | (27.7) | ||
| Overbite | 6 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 10 | |
| (24.0) | (8.3) | (20.0) | (10.0) | (0) | (0) | (0) | (0) | (10.6) | ||
|
| Unilateral | 3 | 0 | 1 | 0 | 0 | 1 | 1 | 2 | 8 |
| (12.0) | (0) | (10.0) | (0) | (0) | (25.0) | (9.1) | (15.4) | (8.5) | ||
| Bilateral | 3 | 2 | 2 | 4 | 1 | 2 | 3 | 3 | 20 | |
| (12.0) | (16.7) | (20.0) | (40.0) | (11.1) | (50.0) | (27.3) | (23.1) | (21.3) | ||
|
| 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | |
| (0) | (8.3 | (0) | (10 | (0) | (0) | (0) | (0) | (2.1) | ||
|
| 8 | 4 | 6 | 7 | 2 | 3 | 6 | 5 | 41 | |
| (32.0) | (33.3) | (60.0) | (70.0) | (22.2) | (75.0) | (54.5) | (38.5) | (43.6) | ||
|
| 2 | 0 | 0 | 2 | 0 | 2 | 0 | 1 | 7 | |
| (8.0) | (0) | (0) | (20.0) | (0) | (50.0) | (0) | (7.7) | (7.4) | ||
ND, neurological disorders; GDD, global developmental disorders; SkD, skeletal dysplasia; HNS, head and neck syndromes; G, genodermatosis; SnD, sensory disorders; ICI, intellectual/cognitive impairment; M, miscellaneous.
Oral functionality of the rare diseases patient group, distributed by categories according to target organ/system.
| Functional Variables | ND | GDD | SkD | HNS | G | SnD | ICI | M | Total | |
|---|---|---|---|---|---|---|---|---|---|---|
|
| 11 | 6 | 3 | 8 | 0 | 3 | 7 | 10 | 48 | |
| (44.0) | (50.0) | (30.0) | (80.0) | (0) | (75.0) | (63.6) | (76.9) | (51.1) | ||
|
| 6 | 4 | 2 | 3 | 0 | 1 | 5 | 5 | 26 | |
| (24.0) | (33.3) | (20.0) | (30.0) | (0) | (25.0) | (45.4) | (38.5) | (27.7) | ||
|
| Lingual | 6 | 6 | 3 | 3 | 0 | 1 | 5 | 5 | 29 |
| (24.0) | (50.0) | (30.0) | (30.0) | (0) | (25.0) | (45.5) | (38.5) | (30.9) | ||
| Lower lip | 1 | 2 | 0 | 1 | 0 | 0 | 3 | 1 | 8 | |
| (4.0) | (16.7) | (0) | (10.0) | (0) | (0) | (27.3) | (7.7) | (8.5) | ||
|
| Upper | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| (4.0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (1.1) | ||
| Lower | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 3 | |
| (4.0) | (0) | (10.0) | (10.0) | (0) | (0) | (0) | (0) | (3.1) | ||
|
| 11 | 7 | 3 | 5 | 0 | 3 | 6 | 10 | 45 | |
| (44.0) | (58.3) | (30.0) | (50.0) | (0) | (75.0) | (54.5) | (76.9) | (47.9) | ||
|
| Oral | 24 | 12 | 10 | 9 | 9 | 4 | 11 | 12 | 91 |
| (96.0) | (100) | (100) | (90.0) | (100) | (100) | (100) | (92.3) | (96.8) | ||
| Modified consistency | 4 | 1 | 0 | 2 | 0 | 2 | 2 | 1 | 12 | |
| (16.0) | (8.3) | (0) | (20.0) | (0) | (50.0) | (18.2) | (7.7) | (12.8) | ||
| Non-oral | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 3 | |
| (4.0) | (0) | (0) | (10.0) | (0) | (0) | (0) | (7.7) | (3.2) | ||
|
| Bruxism | 9 | 3 | 4 | 2 | 0 | 1 | 4 | 2 | 25 |
| (36) | (25) | (40) | (20) | (0) | (25) | (36.4) | (15.4) | (26.6) | ||
| Chews hands or objects | 3 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 4 | |
| (12) | (0) | (0) | (0) | (0) | (0) | (9.1) | (0) | (4.3) | ||
|
| Hypotonia | 12 | 5 | 1 | 3 | 0 | 0 | 4 | 4 | 29 |
| (48.0) | (41.7) | (10.0) | (30.0) | (0) | (0) | (36.4) | (30.8) | (30.9) | ||
| Hypertonia | 3 | 4 | 5 | 3 | 0 | 4 | 1 | 2 | 22 | |
| (12.0) | (33.3) | (50.0) | (30.0) | (0) | (100) | (9.1) | (15.4) | (23.4) | ||
ND, neurological disorders; GDD, global developmental disorders; SkD, skeletal dysplasia; HNS, head and neck syndromes; G, genodermatosis; SnD, sensory disorders; ICI, intellectual/cognitive impairment; M, miscellaneous.
Reasons for not performing the orthodontic treatment in the rare diseases patient group, distributed by categories according to target organ/system.
| ND | GDD | SkD | HNS | G | SnD | ICI | M | Total | ||
|---|---|---|---|---|---|---|---|---|---|---|
|
| 11 | 6 | 4 | 3 | 1 | 1 | 6 | 6 | 38 | |
| (44.0) | (50.0) | (40.0) | (30.0) | (11.1) | (25) | (54.5) | (46.2) | (40.4) | ||
|
| Any reason | 9 | 6 | 1 | 2 | 0 | 1 | 3 | 4 | 26 |
| (81.8) | (100) | (25.0) | (66.6) | (0) | (100) | (50.0) | (66.6) | (68.4) | ||
| Uncontrolled disease | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 3 | |
| (0) | (0) | (0) | (33.3) | (0) | (0) | (0) | (33.3) | (7.8) | ||
| Pharmacotherapy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | |
| (0) | (0) | (0) | (0) | (0) | (0) | (0) | (16.6) | (2.6) | ||
| Difficulty breathing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | ||
| Lack of collaboration | 9 | 5 | 1 | 2 | 0 | 1 | 2 | 1 | 21 | |
| (81.8) | (83.3) | (25.0) | (66.6) | (0) | (100) | (33.3) | (16.6) | (55.2) | ||
| Small mouth opening | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | |
| (0) | (0) | (0) | (0) | (0) | (100) | (16.6) | (0) | (5.2) | ||
| Difficulty eating | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 3 | |
| (9.0) | (0) | (0) | (66.6) | (0) | (0) | (0) | (0) | (7.8) | ||
| Distress talking | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | |
| (0) | (0) | (0) | (0) | (0) | (100) | (16.6) | (0) | (5.2) | ||
| Exacerbated nausea | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | |
| (0) | (0) | (0) | (0) | (0) | (0) | (16.6) | (0) | (2.6) | ||
| Deficient oral hygiene | 3 | 4 | 0 | 1 | 0 | 1 | 1 | 4 | 14 | |
| (27.2) | (66.6) | (0) | (33.3) | (0) | (100) | (16.6) | (66.6) | (36.8) | ||
| Caries | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 2 | |
| (0) | (0) | (0) | (33.3) | (0) | (100) | (0) | (0) | (5.2) | ||
|
| 6 | 2 | 3 | 1 | 1 | 0 | 5 | 4 | 22 | |
| (54.5) | (33.3) | (75.0) | (33.3) | (100) | (0) | (83.3) | (66.6) | (57.8) | ||
|
| Any opinion | 7 | 4 | 2 | 2 | 1 | 1 | 4 | 6 | 27 |
| (63.6) | (66.6) | (50.0) | (66.6) | (100) | (100) | (66.6) | (100) | (71.0) | ||
| Wait for bone growth | 1 | 2 | 1 | 1 | 1 | 1 | 3 | 3 | 13 | |
| (9.0) | (33.3) | (25.0) | (33.3) | (100) | (100) | (50.0) | (50.0) | (34.2) | ||
| Wait for tooth replacement | 6 | 4 | 2 | 2 | 1 | 1 | 4 | 6 | 26 | |
| (54.5) | (66.6) | (50.0) | (66.6) | (100) | (100) | (66.5) | (100) | (68.4) | ||
| Surgical indication | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 3 | |
| (0) | (0) | (25.0) | (33.3) | (100) | (0) | (0) | (0) | (7.8) | ||
The percentage (%) signs are with respect to the number of individuals in each category of the RDG without orthodontic treatment; * % with respect to the number of individuals in each category of the RDG. ND, neurological disorders; GDD, global developmental disorders; SkD, skeletal dysplasia; HNS, head and neck syndromes; G, genodermatosis; SnD, sensory disorders; ICI, intellectual/cognitive impairment; M, miscellaneous.
Characteristics of the orthodontic treatment in the rare diseases patient group, distributed by categories according to target organ/system.
| ND | GDD | SkD | HNS | G | SnD | ICI | M | Total | ||
|---|---|---|---|---|---|---|---|---|---|---|
|
| 14 | 6 | 6 | 7 | 8 | 3 | 5 | 7 | 56 | |
| (56.0) | (50.0) | (60.0) | (70.0) | (88.8) | (75.0) | (45.5) | (53.9) | (59.5) | ||
|
| 7 | 2 | 2 | 3 | 0 | 1 | 1 | 1 | 17 | |
| (50.0) | (33.3) | (33.3) | (42.8) | (0) | (33.3) | (20.0) | (14.2) | (30.3) | ||
|
| Removable | 8 | 4 | 3 | 3 | 0 | 1 | 3 | 3 | 25 |
| (57.1) | (66.6) | (50) | (42.8) | (0) | (33.3) | (60.0) | (42.8) | (44.6) | ||
| Fixed | 10 | 6 | 4 | 7 | 8 | 3 | 4 | 7 | 49 | |
| (71.7) | (100) | (66.6) | (100) | (100) | (100) | (80.0) | (100) | (87.5) | ||
| Removable and Fixed | 4 | 4 | 1 | 3 | 0 | 1 | 2 | 3 | 18 | |
| (28.5) | (66.6) | (16.6) | (42.8) | (0) | (33.3) | (40.0) | (42.8) | (32.1) | ||
|
| Removable | 22.3 | 19.2 | 22.3 | 18.3 | 0 | 10.0 | 28.0 | 22.0 | 20.3 |
| [9–36] | [8–26] | [9–40] | [12–24] | [0] | [10–10] | [12–48] | [18–24] | [8–48] | ||
| Fixed | 23.5 | 23.6 | 38.7 | 24.8 | 45.7 | 54 | 35.5 | 31.4 | 34.6 | |
| [3–38] | [9–32] | [17–60] | [4–44] | [6–74] | [24–78] | [8–50] | [22–40] | [3–78] | ||
| Removable and Fixed | 27.9 | 36.5 | 37.0 | 32.7 | 45.7 | 57.3 | 45.2 | 40.8 | 39.6 | |
| [3–72] | [26–49] | [37–37] | [16–57] | [6–74] | [57–57] | [32–62] | [22–60] | [3–88] | ||
|
| 9 | 3 | 6 | 6 | 6 | 2 | 4 | 5 | 41 | |
| (64.2) | (50.0) | (100) | (85.7) | (75.0) | (66.6) | (80.0) | (71.4) | (73.2) | ||
|
| Any complication | 5 | 3 | 4 | 6 | 5 | 1 | 3 | 3 | 30 |
| (35.7) | (50.0) | (66.6) | (85.7) | (62.5) | (33.3) | (60.0) | (42.8) | (53.5) | ||
| Gingivitis | 5 | 3 | 3 | 6 | 5 | 1 | 3 | 3 | 29 | |
| (35.7) | (50.0) | (50) | (85.7) | (62.5) | (33.3) | (60.0) | (42.8) | (51.7) | ||
| Caries | 0 | 1 | 1 | 3 | 0 | 0 | 1 | 0 | 6 | |
| (0) | (16.6) | (16.6) | (42.8) | (0) | (0) | (20.0) | (0) | (10.7) | ||
| Rhizolysis | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | |
| (0) | (16.6) | (16.6 | (0) | (0) | (0) | (0) | (0) | (3.5) | ||
| Ulcer | 1 | 0 | 1 | 5 | 0 | 0 | 0 | 0 | 7 | |
| (7.1) | (0) | (16.6) | (71.4) | (0) | (0) | (0) | (0) | (12.5) | ||
|
| Uncontrolled systemic disease | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 3 |
| (14.2) | (0) | (0) | (14.2) | (0) | (0) | (0) | (0) | (5.3) | ||
|
| Any complication | 7 | 2 | 6 | 6 | 4 | 1 | 4 | 5 | 35 |
| (50.0) | (33.3) | (100) | (85.7) | (50.0) | (33.3) | (80.0) | (71.4) | (62.5) | ||
| Displaced arch | 0 | 0 | 0 | 2 | 4 | 1 | 1 | 1 | 9 | |
| (0) | (0) | (0) | (28.5) | (50.0) | (33.3) | (20.0) | (14.2) | (16.0) | ||
| Recurrent debonding | 6 | 2 | 4 | 6 | 3 | 1 | 3 | 4 | 29 | |
| (42.8) | (33.3) | (66.6) | (85.7) | (37,5) | (33.3) | (60.0) | (57.1) | (51.7) | ||
| Seldom used | 1 | 0 | 3 | 3 | 0 | 0 | 1 | 2 | 10 | |
| (7.1) | (0) | (50.0) | (42.8) | (0) | (0) | (20.0) | (28.5) | (17.8) | ||
| Breakage | 5 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 8 | |
| (35.7) | (0) | (0) | (14.2) | (12.5) | (0) | (0) | (14.2) | (14.2) | ||
| Loss | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | ||
|
| Temporary | 5 | 2 | 1 | 4 | 0 | 0 | 0 | 0 | 12 |
| (35.7) | (33.3) | (16.6) | (57.1) | (0) | (0) | (0) | (0) | (21.4) | ||
| Definitive | 0 | 0 | 2 | 0 | 2 | 0 | 0 | 0 | 4 | |
| (0) | (0) | (33.3) | (0) | (25.0) | (0) | (0) | (0) | (7.1) | ||
The percentage signs are with respect to the number of individuals in each category of the RDG with orthodontic treatment; * % with respect to the number of individuals in each category of the RDG. ND, neurological disorders; GDD, global developmental disorders; SkD, skeletal dysplasia; HNS, head and neck syndromes; G, genodermatosis; SnD, sensory disorders; ICI, intellectual/cognitive impairment; M, miscellaneous; TxD, mean treatment duration (in months).
Oral/dental manifestations of the rare diseases patient group (RDG) and systemically healthy control group (SHCG).
| Dental Abnormalities | RDG | SHCG |
| |
|---|---|---|---|---|
|
| Chronology | 8 (8.5) | 8 (8.5) | 1.000 (1) |
| Ectopia | 18 (19.1) | 19 (20.2) | 0.854 (1) | |
|
| Agenesis | 23 (24.5) | 4 (4.3) | <0.001 (1) |
| Supernumerary | 5 (5.3) | 0 (0) | - | |
|
| Size | 6 (6.4) | 5 (5.4) | 0.027 (2) |
| Appearance | 8 (8.5) | 4 (4.3) | 0.233 (1) | |
|
| Enamel | 11 (11.7) | 2 (2.1) | 0.010 (2) |
| Dentin | 1 (1.1) | 0 (0) | ||
(1) chi-squared test; (2) Fisher’s exact test.
Orthodontic manifestations of the rare diseases patient group (RDG) and systemicallyhealthy control group (SHCG).
| Orthodontic Variables | RDG | SHCG |
| |
|---|---|---|---|---|
|
| I | 18 (19.1) | 30 (31.9) | 0.060 (1) |
| II | 37 (39.4) | 38 (40.4) | ||
| III | 39 (41.5) | 26 (27.7) | ||
|
| Maxillary | 23 (24.5) | 6 (6.4) | 0.002 (1) |
| Mandibular | 21 (22.3) | 22 (23.4) | ||
| Mixed | 50 (53.2) | 66 (70.2) | ||
|
| Mesofacial | 56 (59.6) | 62 (66) | 0.114 (1) |
| Brachyfacial | 4 (4.3) | 9 (9.6) | ||
| Dolichofacial | 34 (36.2) | 23 (24.5) | ||
|
| Open bite | 26 (27.7) | 20 (21.3) | 0.309 (1) |
| Overbite | 10 (10.6) | 6 (6.4) | 0.013 (1) | |
|
| Unilateral | 8 (8.5) | 17 (18.1) | 0.073 (1) |
| Bilateral | 20 (21.3) | 12 (12.8) | ||
|
| 2 (2.1) | 4 (4.3) | 0.682 (2) | |
|
| 41 (43.6) | 52 (55.3) | 0.109 (1) | |
|
| 7 (7.4) | 0 (0) | 0.007 (1) | |
(1) chi-squared test; (2) Fisher’s exact test.
Oral functionality of the rare diseases patient group (RDG) and systemically healthy control group (SHCG).
| Functional Variables | RDG | SHCG |
| |
|---|---|---|---|---|
|
| 48 (51.1) | 24 (25.5) | <0.001 (1) | |
|
| 26 (27.7) | 2 (2.1) | <0.001 (1) | |
|
| Lingual | 29 (30.9) | 2 (2.1) | <0.001 (1) |
| Lower lip | 8 (8.5) | 0 (0) | ||
|
| Upper | 1 (1) | 2 (2.1) | 0.621 (2) |
| Lower | 3 (3.1) | 0 (0) | ||
|
| 45 (47.9) | 13 (13.8) | <0.001 (1) | |
|
| Modified consistency | 12 (12.8) | 0 (0) | <0.001 (1) |
| Non-oral | 3 (3.2) | 0 (0) | 0.246 (2) | |
|
| Bruxism | 25 (26.6) | 12 (12.8) | 0.017 (1) |
| Chews hands or objects | 4 (4.3) | 0 (0) | 0.121 (1) | |
|
| Hypotonia | 29 (30.9) | 10 (10.6) | <0.001 (1) |
| Hypertonia | 22 (23.4) | 9 (9.6) | ||
(1) chi-squared test; (2) Fisher’s exact test.
Characteristics of the orthodontic treatment in the rare diseases patient group (RDG) and systemically healthy control group (SHCG).
| Variables of Orthodontic Treatment | RDG | SHCG |
| |
|---|---|---|---|---|
|
| 56 (59.2) | 88 (93.6) | <0.001 (1) | |
|
| Desensitization | 17 (18.1) | 4 (4.3) | 0.003 (1) |
| General dental desensitization | 17 (18.1) | 4 (4.3) | 0.003 (1) | |
| Orthodontic desensitization | 17 (18.1) | 0 (0) | <0.001 (1) | |
|
| Removable | 25 (26.6) | 24 (25.5) | 0.868 (1) |
| Fixed | 49 (52.1) | 69 (73.4) | 0.003 (1) | |
| Both | 18 (19.1) | 5 (5.3) | 0.004 (1) | |
|
| Removable | 21.5 [8–48] | 18.9 [1–26] | 0.318 (3) |
| Fixed | 32.3 [3–78] | 28.2 [6–48] | 0.450 (3) | |
| Both | 37.9 [3–88] | 27.2 [15–48] | <0.001 (3) | |
|
| 42 (44.7) | 26 (27.7) | 0.015 (1) | |
|
| ≥1 | 31 (33) | 14 (14.9) | 0.004 (1) |
| Gingivitis | 30 (31.9) | 14 (14.9) | 0.006 (1) | |
| Caries | 6 (6.4) | 0 (0) | 0.013 (1) | |
| Radicular resorption | 2 (2.1) | 0 (0) | 0.497 (2) | |
| Ulcers | 7 (7.4) | 0 (0) | 0.007 (1) | |
|
| Uncontrolled systemic disease | 3 (3.2) | - | 0.246 (2) |
|
| ≥1 | 35 (37.2) | 18 (19.1) | 0.006 (1) |
| Displaced arch | 9 (9.6) | 4 (4.3) | 0.151 (1) | |
| Recurrent debonding | 29 (30.9) | 12 (12.8) | 0.003 (1) | |
| Seldom used | 10 (10.6) | 8 (8.5) | 0.620 (1) | |
| Breakage | 8 (8.5) | 4 (4.3) | 0.233 (1) | |
| Loss | 0 (0) | 0 (0) | - | |
|
| Temporary | 13 (13.8) | 8 (8.5) | 0.056 (2) |
| Definitive | 4 (4.3) | 0 (0) | ||
The percentages are with respect to the number of individuals in each group; ≥1, some complication; (1) chi-squared test; (2) Fisher’s exact test; (3) Wilcoxon rank-sum test with continuity correction.